Noticias de Eulerpool Oryzon Genomics

Oryzon Genomics Eulerpool-AFX

Oryzon Genomics Noticias de Acciones

Oryzon Genomics es observado por muchos periodistas e inversores en todo el mundo. Aquí recopilamos las noticias más recientes de Oryzon Genomics.

• 11 de septiembre ·

  Yahoo
  ORYZON Receives “Intention to Grant” Communication for Patent Relating to the Use of Vafidemstat in Borderline Personality Disorder
• 9 de septiembre ·

  Yahoo
  ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in First-Line Acute Myeloid Leukemia
• 3 de septiembre ·

  Yahoo
  ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat with Additional “Decision to Grant” Communications
• 29 de agosto ·

  Yahoo
  ORYZON to Provide Corporate Progress Updates at Several Events in September
• 31 de julio ·

  Yahoo
  ORYZON reports financial results and corporate update for half-year ending June 30, 2024
• 8 de julio ·

  Yahoo
  ORYZON Receives “Decision to grant” for Two Important Patents for Vafidemstat in Japan
• 28 de junio ·

  Yahoo
  ORYZON Announces Voting Results from its 2024 Annual General Meeting of Shareholders
• 26 de junio ·

  Yahoo
  ORYZON Announces Presentation of Final Data From PORTICO, Vafidemstat’s Global Phase IIb Trial in Borderline Personality Disorder, at the 37th ECNP Annual Conference
• 14 de junio ·

  Yahoo
  ORYZON Presents Preliminary Data From Ongoing Phase Ib FRIDA Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory FLT3-mut AML Patients at EHA-2024
• 3 de junio ·

  Yahoo
  ORYZON Announces Journal Publication of Final Phase IIa ALICE Results with Iadademstat in The Lancet Hematology